Search research articles
Contact Us
Filters
Showing results (81-90 of 97) with videos related to
Page
of 10
Sort By:
Nature Neuroscience
|
June 14, 2016
Zeb2 recruits HDAC-NuRD to inhibit Notch and controls Schwann cell differentiation and remyelination
Lai Man Natalie Wu, Jincheng Wang, Andrea Conidi, et al.
ACS Chemical Neuroscience
|
January 24, 2024
Identification and In Vivo Evaluation of Myelination Agent PIPE-3297, a Selective Kappa Opioid Receptor Agonist Devoid of β-Arrestin-2 Recruitment Efficacy
Thomas O Schrader, Kym I Lorrain, Didier Bagnol, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
July 31, 2024
Targeting the muscarinic M1 receptor with a selective, brain-penetrant antagonist to promote remyelination in multiple sclerosis
Michael M Poon, Kym I Lorrain, Karin J Stebbins, et al.
Neuron
|
August 7, 2018
Enhancing Oligodendrocyte Myelination Rescues Synaptic Loss and Improves Functional Recovery after Chronic Hypoxia
Fei Wang, Yu-Jian Yang, Nian Yang, et al.
Nature Medicine
|
July 12, 2024
Author Correction: Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis
Feng Mei, Stephen P J Fancy, Yun-An A Shen, et al.
Nature Medicine
|
July 7, 2014
Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis
Feng Mei, Stephen P J Fancy, Yun-An A Shen, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
December 14, 2011
Neurite outgrowth inhibitor Nogo-A establishes spatial segregation and extent of oligodendrocyte myelination
S Y Christin Chong, Sheila S Rosenberg, Stephen P J Fancy, et al.
Multiple Sclerosis and Related Disorders
|
April 9, 2022
A hormonal therapy for menopausal women with MS: A phase Ib/IIa randomized controlled trial
Riley Bove, Annika Anderson, William Rowles, et al.
Lancet (London, England)
|
October 15, 2017
Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial
Ari J Green, Jeffrey M Gelfand, Bruce A Cree, et al.
Brain : a Journal of Neurology
|
December 16, 2017
Clemastine rescues myelination defects and promotes functional recovery in hypoxic brain injury
Bruce A C Cree, Jianqin Niu, Kimberly K Hoi, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 97) with videos related to
Sort By:
Page
of 10
Nature Neuroscience
|
June 14, 2016
Zeb2 recruits HDAC-NuRD to inhibit Notch and controls Schwann cell differentiation and remyelination
Lai Man Natalie Wu, Jincheng Wang, Andrea Conidi, et al.
ACS Chemical Neuroscience
|
January 24, 2024
Identification and In Vivo Evaluation of Myelination Agent PIPE-3297, a Selective Kappa Opioid Receptor Agonist Devoid of β-Arrestin-2 Recruitment Efficacy
Thomas O Schrader, Kym I Lorrain, Didier Bagnol, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
July 31, 2024
Targeting the muscarinic M1 receptor with a selective, brain-penetrant antagonist to promote remyelination in multiple sclerosis
Michael M Poon, Kym I Lorrain, Karin J Stebbins, et al.
Neuron
|
August 7, 2018
Enhancing Oligodendrocyte Myelination Rescues Synaptic Loss and Improves Functional Recovery after Chronic Hypoxia
Fei Wang, Yu-Jian Yang, Nian Yang, et al.
Nature Medicine
|
July 12, 2024
Author Correction: Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis
Feng Mei, Stephen P J Fancy, Yun-An A Shen, et al.
Nature Medicine
|
July 7, 2014
Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis
Feng Mei, Stephen P J Fancy, Yun-An A Shen, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
December 14, 2011
Neurite outgrowth inhibitor Nogo-A establishes spatial segregation and extent of oligodendrocyte myelination
S Y Christin Chong, Sheila S Rosenberg, Stephen P J Fancy, et al.
Multiple Sclerosis and Related Disorders
|
April 9, 2022
A hormonal therapy for menopausal women with MS: A phase Ib/IIa randomized controlled trial
Riley Bove, Annika Anderson, William Rowles, et al.
Lancet (London, England)
|
October 15, 2017
Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial
Ari J Green, Jeffrey M Gelfand, Bruce A Cree, et al.
Brain : a Journal of Neurology
|
December 16, 2017
Clemastine rescues myelination defects and promotes functional recovery in hypoxic brain injury
Bruce A C Cree, Jianqin Niu, Kimberly K Hoi, et al.
Page
of 10